Dr. Steinlauf is fully trained in all aspects of gastroenterology but sub specializes in the diagnosis and treatment of the inflammatory bowel diseases (IBD), ulcerative colitis and Crohn -?s disease. In addition, Dr. Steinlauf is extensively involved in the study of new and exciting research protocols which will hopefully lead to a better understanding of IBD and improve on current management strategies.
MD, S.U.N.Y., Health Science Center
Residency, Internal Medicine
Columbia-Presbyterian Medical Ctr.
Yale-New Haven Hospital
Current protocols in progress for Ulcerative Colitis include: Rosiglitazone, the probiotic VSL#3, Visilizumab, and Luekocytapharesis.
Current protocols for in progress for Crohn -?s disease include: extracorporeal photoimmune therapy with UVADEX, Sargrostim (Leukine), anti-IL-12, Adalimumab, Visilizumab and high dose asacol.
Steinlauf AF, Traube M. Esophageal Reflux and Anesthetic Risk: Proton Pump Inhibitors and Other New Agents. Anesthesiol Clin North America: Annual of Anesthetic Pharmacology 1998;(2): 17-36.
Steinlauf AF, Traube M, Neitlich JD, Cooney EL. Clostridium difficile Colitis: A Possible Cause of Unexplained Elevation of Serum Alkaline Phosphatase Levels in Patients with AIDS. Clin Infect Dis 1998 May; 26(5): 1248-9.
Steinlauf AF, Garcia-Tsao G, Zakko MF, Dickey K, Gupta T, Groszmann RJ. Low Dose Midazolam Sedation: An Option For Patients Undergoing Serial Hepatic Venous Pressure Measurements. Hepatology 1999 Apr; 29(4): 1070-3.
Steinlauf AF, Chan PK, Traube M. Gastrointestinal Complications. In: Burrow GN, Duffy TP, Copel JA, editors. Medical Complications During Pregnancy. 6th ed. Philadelphia, W.B. Saunders Co.; 2004. pp259-278.
Steinlauf AF, Present DH. Medical Management of the Pregnant Patient with Inflammatory Bowel Disease. Gastroenterol Clin North Am. 2004 Jun; 33(2): 361-85.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Steinlauf during 2016 and/or 2017. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.